DEPARTMENT OF SOCIAL AND HEALTH SERVICES MEDICAL ASSISTANCE ADMINISTRATION Olympia, Washington

To: Pharmacies Memorandum No: 05-01 MAA

All Prescribers Issued: January 3, 2004

Managed Care Plans

Nursing Home Administrators

For More Information, call:

From: Douglas Porter, Assistant Secretary 1-800-562-6188

Medical Assistance Administration

Subject: Prescription Drug Program: Expedited Prior Authorization Updates

Effective the week of February 7, 2005, and after, the Medical Assistance Administration (MAA) will implement the changes to expedited prior authorization codes and criteria for MAA's Prescription Drug Program outlined in this memorandum.

Changes to Expedited Prior Authorization Codes and Criteria

Drug	Code	Criteria
Enbrel® (etanercept)	017	Treatment of rheumatoid arthritis or ankylosing spondylitis when prescribed by a rheumatologist up to 50mg subcutaneously per week for patients who have had an inadequate response to one or more Disease Modifying Anti Rheumatoid Drug (DMARD).
	024	Treatment of psoriatic arthritis when prescribed by a rheumatologist or dermatologist up to 50mg subcutaneously per week for patients who have had an inadequate response to one or more DMARD.
	025	Treatment of plaque psoriasis in patients 18 years of age and older when prescribed by a rheumatologist or dermatologist. Dose not to exceed 50mg subcutaneously twice weekly for the first three months of therapy and not to exceed 50mg weekly thereafter.

Billing Instructions Replacement Pages

Attached are replacement pages H.9-H.10 for MAA's current *Prescription Drug Program Billing Instructions*.

How can I get MAA's provider issuances?

To obtain MAA's provider numbered memoranda and billing instructions, go to MAA's website at http://maa.dshs.wa.gov (click on the Billing Instructions/Numbered Memoranda or Provider Publications/Fee Schedules link).

To request a free hard copy from the Department of Printing:

- Go to: http://www.prt.wa.gov/ (Orders filled daily)
 Click on General Store. Follow prompts to Store Lobby → Search by Agency →
 Department of Social and Health Services → Medical Assistance Administration → desired issuance; or
- **Fax/Call:** Dept. of Printing/Attn: Fulfillment at FAX (360) 586-6361/ telephone (360) 586-6360. (Orders may take up to 2 weeks to fill.)

Prescription Drug Program

Drug	Code	Criteria	Drug	Code	Criteria
Ouragesic [®] Tentanyl)	040	Diagnosis of cancer-related pain.	Geodon® (ziprasidone HCl)	046	All of the following must apply: a) There must be an appropriate DSM IV diagnosis; and
E nbrel[®] etanercept)	017	Treatment of rheumatoid arthritis or ankylosing spondylitis when prescribed by a rheumatologist up to 50mg subcutaneously per week for patients who have had an inadequate response to one or more Disease Modifying Anti Rheumatoid Drug (DMARD).	S C C S ii	Seroquel [®] contraindid QT prolon yndrome) nfarction,	b) Patient is 6 years of age or of decodon® prolongs the QT interval > Risperdal® > Zyprexa®), it is cated in patients with a known his gation (including a congenital lone, with recent acute myocardial or with uncompensated heart fail
	024	Treatment of psoriatic arthritis when prescribed by a rheumatologist or dermatologist up to 50mg subcutaneously per week for patients who have had an inadequate response to		and in com he QT into 021	nbination with other drugs that property. Treatment of occasional consti
	025	one or more DMARD. Treatment of plaque psoriasis in patients 18 years of age and older when	Powder® (polyethylene glyc		Must have tried and failed a le costly alternative.
		prescribed by a rheumatologist or dermatologist. Dose not to exceed 50mg subcutaneously twice weekly for the first three months of therapy and not to exceed 50mg weekly thereafter.	Humira Injection [®] (adalimumab)	028	Treatment of rheumatoid arthrowhen prescribed by a rheumatofor patients who have tried and one or more DMARD. Dose nexceed 40mg subcutaneously etwo weeks if patient is also recommended.
azaclo[®] lozapine)	012	All of the following must apply: a) There must be an appropriate DSM IV diagnosis present as determined by a qualified mental health			methotrexate, or up to 40mg subcutaneously every week if j is not receiving methotrexate concomitantly.
		professional; and b) Patient is 18 years of age or older; and c) Must be prescribed by a psychiatrist, neurologist, or psychiatric ARNP with prescriptive authority approved for this drug	Infergen [®] (interferon alphco	134 on-1)	Treatment of chronic hepatitis in patients 18 years of age and with compensated liver disease have anti-HCV serum antibodi and/or presence of HCV RNA.
	class, or in consultation with one of the above; and d) Must have tried and failed generic	Intron A [®] (interferon alpha- recombinant)	030 2b	Diagnosis of hairy cell leukem in patients 18 years of age and	
o calin[®] lexmethylphenid	late HCl)	clozapine. See criteria for Concerta [®] .		031	Diagnosis of recurring or refraction condyloma acuminate (externation genital/perianal area) for intralesional treatment in patient 18 years of age and older.
				032	Diagnosis of AIDS-related Kaj sarcoma in patients 18 years of and older.

Prescription Drug Program

Drug	Code	Criteria
	033	Diagnosis of chronic hepatitis B in patients 1 year of age and older.
	107	Diagnosis of malignant melanoma in patients 18 years of age and older.
	109	Treatment of chronic hepatitis C in patients 18 years of age and older.
	135	Diagnosis of follicular non-Hodgkin's lymphoma in patients 18 years of age and older.
Kadian® (morphine sulfate)	040	Diagnosis of cancer-related pain.
Kineret Injection [®] (anakinra)	029	Treatment of rheumatoid arthritis when prescribed by a rheumatologist for patients 18 years of age and older who have tried and failed one or more DMARD. Daily dose not to exceed 100mg subcutaneously.
Kytril [®] (granisetron HCl)	127	Prevention of nausea or vomiting associated with moderately to highly emetogenic cancer chemotherapy.
	128	Prevention of nausea or vomiting associated with radiation therapy.
Lamisil [®] (terbinafine HCl)		Treatment of onychomycosis for up to 12 months per nail is covered if patient has one of the following conditions:
	042	Diabetic foot;
	043	History of cellulitis secondary to onychomycosis and requiring systemic antibiotic therapy; or
	045	Fingernail involvement with or without chronic paronychia.
Levorphanol	040	Diagnosis of cancer-related pain.

Drug	Code	Criteria
Lotrel® (amlodipine besylate/benaze	038	Treatment of hypertension as a second line agent when blood pressure is not controlled by any:
		 a) ACE inhibitor alone; or b) Calcium channel blocker alone; or c) ACE inhibitor and a calcium channel blocker as two separate concomitant prescriptions.
Marinol [®] (dronabinol)	035	Diagnosis of cachexia associated with AIDS
	036	Diagnosis of cancer and failure of all other drugs to adequately treat nausea and vomiting related to radiation or chemotherapy.
Metadate Cl		See criteria for Concerta [®] .
Miralax [®] (polyethylene gl	ycol)	See criteria for Glycolax Powder®
Naltrexone		See criteria for ReVia®.
Nephrocaps	® 096	Treatment of patients with renal disease.
(ferre folice Nep Vitar Nep (folice com, Nep (fe fu vitar Nep (fe fu	ohro-FER® ous fumarate/ oucid) ohro-Vite® min B comp W-C ohro-Vite R2 oucid/vitamin B p W-C) ohro-Vite+F marate/FA/ min B comp W-C ohron FA® marate/doss/ B comp & C)	K® E®